What is the difference between Tesamorelin and Sermorelin?

Tesamorelin is FDA-approved (for HIV-associated lipodystrophy). Sermorelin's FDA approval was withdrawn in 2008; it is now only available through compounding pharmacies.

Which is better, Tesamorelin or Sermorelin?

It depends on your goals. Choose Tesamorelin for visceral fat reduction is the primary goal (15 to 18% trunk fat reduction in trials). Choose Sermorelin for cost is a major factor ($175 to $225/month compounded vs $3,085/month brand tesamorelin).

Tesamorelin vs Sermorelin

Peptide Schedule Research TeamReviewed Apr 202619 Citations

Side-by-side comparison of dosage, benefits, and side effects.

Tesamorelin

Growth Hormone26-38 min

Eighteen percent less visceral fat at six months. That's the headline number from the TRIM trials, and it holds up across 816 participants in a double-blind, placebo-controlled Phase 3 program. The tesamorelin peptide (trade name Egrifta SV, also marketed as Egrifta WR, compound code TH9507) is a synthetic 44-amino-acid GHRH analog with an added trans-3-hexenoic acid modification that extends stability beyond native GHRH. The mechanism is straightforward. Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs, producing pulsatile GH release rather than flat tonic elevation. That GH pulse drives hepatic IGF-1 production, and IGF-1 mediates the downstream lipolysis, targeting visceral adipose depots. Subcutaneous bioavailability runs below 4% per the FDA label (Section 12.3), yet the receptor-level response is potent enough to produce measurable body composition changes. In clinical practice, the FDA approved tesamorelin in 2010 for HIV-associated lipodystrophy with excess visceral adipose tissue. The TRIM trial data (PMID 20101189) showed a mean visceral fat reduction of 26 cm squared versus a 3.8 cm squared gain on placebo, with waist circumference dropping 2.5 cm. Beyond HIV, the off-label use has expanded considerably. Stanley and colleagues published a 2019 Lancet HIV trial (PMID 31611038) showing 35% of patients achieved liver fat below 5% at 12 months, establishing a potential NAFLD benefit. Baker et al. (PMID 22869065) demonstrated improved executive function in older adults and MCI patients after 20 weeks of GHRH treatment in a 152-person RCT. Community dosing mirrors the FDA label at 2 mg daily subcutaneous abdomen, with most protocols running 12 to 26 weeks followed by a rest period.

View full guide →

Sermorelin

Growth Hormone~10-20 min

Twenty-nine amino acids. That's what separates the sermorelin peptide (also known as Geref or GRF 1-29) from the full 44-amino-acid endogenous GHRH molecule, and those 29 amino acids are the only ones that matter for receptor binding. Sermorelin acetate (CAS 86168-78-7) is a synthetic analog of human GHRH(1-29)NH2 that retains complete GHRH receptor affinity on pituitary somatotroph cells. The mechanism is direct. Sermorelin binds the GHRH receptor, triggering pulsatile GH release that mirrors the body's natural secretion pattern. Unlike exogenous growth hormone injections, this preserves the hypothalamic-pituitary feedback loop. The pituitary decides how much GH to release; sermorelin just gives it a stronger signal to do so. That distinction matters for long-term safety. Vittone and colleagues ran a six-month trial in age-advanced adults (PMID 9141536) using once-daily subcutaneous GHRH analog injections. The results landed on lean mass gains, fat reduction, and improved sleep architecture. The Geref International Study Group (PMID 8772599) confirmed sustained growth velocity in GH-deficient children at 30 mcg/kg/day over 12 to 36 months. Subcutaneous bioavailability sits at approximately 6% per the Geref product label, which is expected for GHRH analogs and still produces reliable pharmacological GH pulses. In practice, sermorelin is the "start here" peptide on r/Peptides (roughly 95,000 subscribers). Community dosing runs 200 to 300 mcg nightly, almost always co-injected with ipamorelin for dual-pathway GH release. Sleep improvement within the first two weeks is the most consistently reported early effect across hundreds of threads. Body composition shifts require two to three months of patience. No new large RCTs for anti-aging indications have been published between 2024 and 2026, so the adult off-label evidence base relies on the 1990s clinical data combined with a large, consistent community experience.

View full guide →

At a Glance

Attribute	Tesamorelin	Sermorelin
Category	Growth Hormone	Growth Hormone
Safety Grade	B	B
Half-Life	26-38 min	~10-20 min
Route	Subcutaneous	Subcutaneous
Vial Sizes	2mg, 5mg	5mg
Beginner Dose	2000mcg Daily	200mcg Daily
Moderate Dose	2000mcg Daily	300mcg Daily
Aggressive Dose	2000mcg Daily	500mcg Daily
Dosing Source	FDA Label	Community
Side Effects	Glucose management is the most important safety concern with tesamorelin. GH-mediated insulin resistance is a class effect of all GHRH analogs, and the FDA label includes specific warnings about new-onset diabetes and glucose intolerance. Fasting glucose and HbA1c must be monitored at baseline, then every three to six months during treatment. A fasting glucose above 126 mg/dL or HbA1c above 6.5% means stopping or significantly adjusting the protocol. Pre-diabetic users and those with metabolic syndrome carry higher risk. The 2024 INSTI-era study (n=61, PMID 38905488) confirmed that tesamorelin on modern ART regimens did not exacerbate glycemic control, but that data applies to the HIV population specifically. Active malignancy is an absolute contraindication. Tesamorelin raises IGF-1, and IGF-1 promotes cell proliferation. The FDA label explicitly contraindicates use in patients with active or recurrent cancer. Newly diagnosed malignancy during treatment requires immediate discontinuation. This is not a theoretical concern; it's a black-box-level warning. Antibody formation occurs in approximately 50% of patients on continuous dosing per TRIM trial immunogenicity data. Most antibodies are non-neutralizing and don't reduce clinical effect. A subset of 10 to 15% develop neutralizing antibodies that blunt the VAT reduction response. Signs include declining IGF-1 despite consistent dosing and plateau or reversal of fat loss after initial progress. Cycling (26 weeks on, 4 to 8 weeks off) allows antibody titers to decline and typically restores responsiveness on re-challenge. Injection site reactions are common in the first week: redness, pain, and induration at the abdominal injection site. The FDA label specifies abdominal subcutaneous injection only for this indication. Repeated injection into the same small area can cause localized lipoatrophy (skin dimpling) because tesamorelin triggers local lipolysis. Systematic site rotation across the abdomen prevents this. Avoid the area within 2 cm of the umbilicus and any scarred or bruised skin. Joint pain and peripheral edema affect some users in the first two to four weeks as IGF-1 rises and fluid retention increases. Community reports describe this as self-resolving in most cases. If symptoms persist beyond four weeks, reducing the dose to 1 mg per day usually resolves them. NSAIDs help short-term for joint pain; leg elevation helps for lower extremity edema. Pregnancy is contraindicated due to potential fetal harm per the FDA label. Breastfeeding lacks sufficient safety data. Patients with disruption of the hypothalamic-pituitary axis from hypophysectomy, pituitary tumor, or pituitary surgery should not use tesamorelin, as the mechanism requires functional pituitary somatotrophs. Known hypersensitivity to tesamorelin or mannitol (used as an excipient in the formulation) is a contraindication. When to see a doctor: persistent edema beyond four weeks, fasting glucose above 126 mg/dL, joint pain unresponsive to dose reduction, any new or worsening mass or tumor, or signs of glucose intolerance.	Antibody formation is the primary long-term safety concern with sermorelin. The Geref prescribing information documents that approximately 70% of patients on continuous daily dosing develop anti-sermorelin antibodies by 18 months. These antibodies neutralize the peptide and progressively reduce its ability to stimulate GH release. This isn't a minor footnote. Users who skip cycling and run sermorelin continuously for six-plus months commonly report complete loss of effect. The antibody response is antigen-driven, so reducing injection frequency (5 days on, 2 days off) and taking periodic four-week breaks are the established mitigation strategies. Facial flushing is the most common acute side effect. It typically occurs 20 to 30 minutes after injection and results from the vasodilatory response to acute GH release. Community reports and clinical data both describe this as transient, resolving within an hour, and most prominent during the first one to three weeks of use. It does not require dose adjustment unless severe. Headache and dizziness post-injection are reported at moderate frequency. Like flushing, these relate to the acute GH pulse. They tend to resolve by weeks three to four without intervention. If persistent, reducing the dose by 50 mcg usually handles it. Injection-site reactions (redness, minor irritation, occasional nodules) are expected with any subcutaneous peptide. Consistent site rotation and allowing refrigerated peptide to reach room temperature before injecting both reduce incidence. Nodules persisting beyond one week warrant switching to a different anatomical region. GH-mediated insulin resistance is a theoretical concern with any GH-raising therapy. Sermorelin produces physiological (not supraphysiological) GH pulses, so the risk is lower than with exogenous GH. Still, fasting glucose monitoring every three months is appropriate, especially for anyone over 40 or carrying metabolic risk factors. A fasting glucose above 126 mg/dL means stopping. GH promotes cell proliferation. Active cancer, a history of malignancy, or active pituitary tumors are absolute contraindications. If IGF-1 surpasses the age-adjusted upper normal range, the dose should be reduced or the protocol discontinued. Untreated hypothyroidism impairs GH response to sermorelin (Geref contraindications). GH also accelerates T4-to-T3 conversion, so thyroid function may shift during use. Baseline thyroid panel is recommended. Pregnancy and breastfeeding are contraindicated. Effects on fetal development have not been established. When to see a doctor: persistent edema, fasting glucose above 126 mg/dL, joint pain unresponsive to dose reduction, symptoms of intracranial hypertension, or any sign of glucose intolerance.

Key Differences

Tesamorelin is FDA-approved (for HIV-associated lipodystrophy). Sermorelin's FDA approval was withdrawn in 2008; it is now only available through compounding pharmacies.
Both are GHRH analogs that stimulate the pituitary to release growth hormone. Tesamorelin is a modified 44-amino acid peptide; sermorelin is the first 29 amino acids of natural GHRH.
Tesamorelin has a longer half-life (26 to 38 minutes) compared to sermorelin (10 to 20 minutes), though both require daily dosing.
Tesamorelin has stronger clinical evidence for visceral fat reduction. The LIPO-012 trial showed a 15% to 18% reduction in trunk fat at 26 weeks.
Sermorelin is significantly cheaper. Compounded sermorelin runs $175 to $225 per month vs $3,085 per month for brand Egrifta SV (tesamorelin). Compounded tesamorelin is $150 to $300 per month.

When to Choose Tesamorelin

Visceral fat reduction is the primary goal (15 to 18% trunk fat reduction in trials)
You want an FDA-approved GHRH analog with published clinical trial data
HIV-associated lipodystrophy is the indication (on-label use)
You're willing to pay more for stronger evidence and regulatory backing

When to Choose Sermorelin

Cost is a major factor ($175 to $225/month compounded vs $3,085/month brand tesamorelin)
General GH optimization, sleep, and recovery are the goals rather than targeted fat loss
You want a widely available compounding pharmacy option
You plan to stack with a GHRP like ipamorelin for synergy

Can You Stack Tesamorelin + Sermorelin?

Not Recommended

Tesamorelin and sermorelin both work through the GHRH receptor. Using both would cause redundant receptor stimulation with no added benefit. Pick one based on your budget and evidence needs. Either one stacks well with ipamorelin (a GHRP).